Neurocrine biosciences reports patient-reported outcome data from kinect-pro™ study for ingrezza® (valbenazine) capsules in tardive dyskinesia: significant and clinically meaningful improvements in functionality and quality of life measures

San diego , feb. 27, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced top-line data from a phase 4 study, kinect-pro™, demonstrating clinically meaningful and sustained effects of ingrezza® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (td), irrespective of td severity or underlying psychiatric condition. kinect-pro is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically ingrezza, on td using multiple clinically validated scales, including the tardive dyskinesia impact scale used to evaluate the physical, social and emotional impact of involuntary movements.
NBIX Ratings Summary
NBIX Quant Ranking